PT  - JOURNAL ARTICLE
AU  - Anita-Maria Genda
AU  - Lavinia Davidescu
AU  - Ruxandra Ulmeanu
AU  - Monica Ilisie
TI  - Value of adding treatment with lyophilized bacterial lysates in reducing COPD exacerbations in COPD patients risk group C and D
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P3008
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P3008.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P3008.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - Background: An increased frequency of exacerbations in COPD is associated with rapid decline of lung function, while the mechanism of exacerbations are not clear yet. By including in the treatment immunostimulant agents like lyophilized bacterial lysates, we can reduce exacerbations, especially in COPD patients risk groups C and D.Aim:To evaluate the value of adding in the treatment lyophilized bacterial lysates in reducing exacerbations in COPD patients risk groups C and D.Methods: From January to December 2013 were studied 41 patients with COPD groups C and D, admitted in the Municipal Clinic Hospital Oradea,for severe exacerbations.We compared COPD patients at risk groups C and D who had added lyophilized bacterial lysates to their standard medication, to patients with COPD group C and D without immunostimulant treatment added on. We analysed the following data: age, gender, smoking history (PackYear), number of exacerbations/year, number of days of hospitalization, spirometry parameters (FEV1, FEV1/FVC).Results:Of all 41 studied patients, 43,9 % (lot nr I.) were treated with lyophilized bacterial extract and 56,1 % (lot nr. II) had no immunostimulant treatment.The first lot of patients had 2.11 exacerbation/year,while the second category had 2,8 exacerbations/year. Moreover, patients from first lot had less days of hospitalization (11.07 days) as compared to patients from second lot (17.1 days), hence a lowering of 35,3% in the number of days of hospitalization.Conclusions:The treatment with lyophilized bacterial lyzates decreased significantly the number of exacerbations/year and days of hospitalization in patients with COPD risk groups C and D.